Clin2
NCT06694935Possibly a fitRecruiting

Testing QX1206 in type 2 diabetes with fatty liver

Type 2 Diabetes Mellitus (T2DM)Non-Alcoholic Fatty Liver Disease (NAFLD)

Part of Digestive system, Hormones & metabolism clinical trials.

This trial tests a new pill called QX1206 for people who have both Type 2 diabetes and fatty liver disease (NAFLD). The goal is to see if the medicine is safe and can help improve both conditions.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
52 people
Ages
18 years to 64 years
Study type
Interventional

Who can take part

  • You must have both Type 2 Diabetes and nonalcoholic fatty liver disease (NAFLD).
  • You must be 18 to 64 years old.
  • Your BMI must be between 18 and 44.9.
  • You cannot have uncontrolled diabetes or any serious active medical condition.
  • You must not drink heavily or have a history of heavy alcohol use.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07303803Recruiting· Phase 2
Testing Chiglitazar for fatty liver with diabetes

This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.

Beijing, Beijing Municipality
NCT07620366Not yet recruiting· Phase 2
Testing QL2401 for Fatty Liver Disease with Scarring

This study tests a new drug called QL2401 to see if it can improve fatty liver disease (MASH) in people who also have diabetes, obesity, or related conditions. The drug is designed to reduce liver fat and slow scarring.

NCT06519448Enrolling by invitation
Testing a pill for non-alcoholic fatty liver disease

This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.

Prague
NCT07083336Recruiting
Diet study for type 2 diabetes with fatty liver disease

This trial tests a specific medical nutrition therapy diet to see if it can reduce liver fat and improve blood sugar control in people with type 2 diabetes and nonalcoholic fatty liver disease. It may help you manage both conditions with a dietary approach.

Yichang, Hubei
NCT07407634Not yet recruiting· Early Phase 1
Study of a new cholesterol-lowering tablet (XTYW007)

This study tests a new tablet (XTYW007) to see if it’s safe and helps lower cholesterol. It’s for people with certain LDL cholesterol levels and likely for those who have not responded well to standard treatments.

Jilin City, Changchun
NCT06891365Recruiting· Phase 1
Multiple doses of a new drug for fatty liver disease

This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.

Harrow

Hear when a new Type 2 Diabetes Mellitus (T2DM) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.